Palbociclib - Wikipedia
WEBPalbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6 .
Palbociclib: Uses, Dosage, Side Effects, Warnings - Drugs.com
WEBAug 23, 2023 · Palbociclib is used to treat adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. It should always be used in combination with another medicine either: an aromatase inhibitor as initial endocrine …
Palbociclib - NCI - National Cancer Institute
WEBThis page contains brief information about palbociclib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Palbociclib (Ibrance): Uses & Side Effects - Cleveland Clinic
WEBPalbociclib is a medication that stops cancer cells from growing. It treats breast cancer. This type of cancer occurs when cells in your breast grow and divide in an uncontrolled way, creating a mass of tissue called a tumor.
Palbociclib and Letrozole in Advanced Breast Cancer
WEBNov 17, 2016 · Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than...
Ibrance (palbociclib) - Uses, Side Effects, and More - WebMD
WEBAug 15, 2024 · Ibrance (palbociclib) is commonly used for treating breast cancer. It treats breast cancer that is advanced or has spread to other parts of the body (metastatic) and is hormone receptor (HR ...
Palbociclib: Uses, Interactions, Mechanism of Action - DrugBank …
WEBPalbociclib is an endocrine-based chemotherapeutic agent used in combination with other antineoplastic agents to treat HER2-negative and HR-positive advanced or metastatic breast cancer.
Palbociclib (IBRANCE) | FDA
WEBOn March 31, 2017, the U.S. Food and Drug Administration granted regular approval to palbociclib (IBRANCE®, Pfizer Inc.) for the treatment of hormone receptor (HR) positive, human epidermal ...
Palbociclib: MedlinePlus Drug Information
WEBPalbociclib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells.
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
WEBJun 1, 2015 · Palbociclib (Ibrance, Pfizer) is an orally bioavailable small-molecule inhibitor of CDK4 and CDK6, with a high level of selectivity for CDK4 and CDK6 over other cyclin-dependent...
Skip to content